# Ibrutinib Adapted to Response in Patients With CLL

> **NCT05360758** · — · UNKNOWN · sponsor: **Grupo Argentino de Tratamiento de la Leucemia Aguda** · enrollment: 80 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **OTHER:** Evaluation of response to treatment with response-tailored Ibrutinib in patients with chronic lymphocytic leukemia

## Key facts

- **NCT ID:** NCT05360758
- **Lead sponsor:** Grupo Argentino de Tratamiento de la Leucemia Aguda
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-06-01
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05360758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05360758, "Ibrutinib Adapted to Response in Patients With CLL". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05360758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*